Placebo to MK-8189

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Schizophrenia

Phase 1

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

CompletedNCT05953740

Merck Sharp & Dohme LLCSchizophrenia

Start: 2023-09-15End: 2024-02-15Updated: 2025-03-04

Phase 2

Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

CompletedNCT04624243

Merck Sharp & Dohme LLCSchizophrenia

Start: 2020-12-15End: 2024-06-21Updated: 2026-04-29

Related Papers

Phase 2b Trial of the PDE10A Inhibitor MK-8189 in People With an Acute Episode of Schizophrenia.

2026-02-23